Zura Bio Limited - Class A Ordinary shares (NQ:ZURA)

5.405 -0.025 (-0.46%)

Streaming Delayed Price Updated: 11:34 AM EDT, Aug 3, 2026 Add to My Watchlist

Price and Volume

Volume	98,504
Open	5.460
Bid (Size)	5.400 (400)
Ask (Size)	5.410 (400)
Prev. Close	5.430
Today's Range	5.261 - 5.490
52wk Range	1.390 - 7.440
Shares Outstanding	62,064,270
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Analyst Sees Multi-Billion-Dollar Sales Potential for Zura Bio’s Lead Therapy ↗

July 08, 2026

William Blair starts Zura Bio (NASDAQ: ZURA) at Outperform, citing tibulizumab's multibillion-dollar potential in autoimmune disease.

Via Benzinga

Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program

June 29, 2026

From Zura Bio Limited

Via Business Wire

Performance

YTD	-2.6%	-2.6%
1 Month	+0.8%	+0.8%
3 Month	+1.6%	+1.6%
6 Month	-6.3%	-6.3%
1 Year	+270.2%	+270.2%

More News

Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

May 14, 2026

From Zura Bio Limited

Via Business Wire

Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer

May 13, 2026

From Zura Bio Limited

Via Business Wire

ZURA BIO LTD (NASDAQ:ZURA) Q1 2026: Cash Runway Extended Through 2028 as Phase 2 Trials Advance ↗

May 07, 2026

Via Chartmill

Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates

May 07, 2026

From Zura Bio Limited

Via Business Wire

Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

May 04, 2026

From Zura Bio Limited

Via Business Wire

Zura Bio Reports Full Year 2025 Financial Results and Recent Corporate Updates

March 19, 2026

From Zura Bio Limited

Via Business Wire

Zura Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic Sclerosis World Congress

March 05, 2026

From Zura Bio Limited

Via Business Wire

Zura Bio to Participate in Upcoming Investor Conferences

March 02, 2026

From Zura Bio Limited

Via Business Wire

Zura Bio Announces Closing of its $144 Million Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

February 27, 2026

From Zura Bio Limited

Via Business Wire

Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million ↗

February 25, 2026

Via The Motley Fool

This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges ↗

February 25, 2026

Via The Motley Fool

Disc Medicine Lands New $20 Million Investment as FDA Sets Up Potential Q4 Catalyst ↗

February 25, 2026

Via The Motley Fool

Zura Bio Announces Pricing of $125 Million Public Offering of Class A Ordinary Shares and Pre-Funded Warrants

February 25, 2026

From Zura Bio Limited

Via Business Wire

Zura Bio Announces Proposed Public Offering of Class A Ordinary Shares and Pre-Funded Warrants

February 24, 2026

From Zura Bio Limited

Via Business Wire

Zura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to Board of Directors

February 23, 2026

From Zura Bio Limited

Via Business Wire

Zura Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit

February 04, 2026

From Zura Bio Limited

Via Business Wire

Zura Bio Appoints Immunology Industry Leader Sandeep Kulkarni, M.D. as Chief Executive Officer

January 21, 2026

From Zura Bio Limited

Via Business Wire

Zura Bio Reports Business Updates and Outlook for 2026

January 12, 2026

From Zura Bio Limited

Via Business Wire

Zura Bio Reports Third Quarter 2025 Financial Results and Recent Corporate Updates

November 13, 2025

From Zura Bio Limited

Via Business Wire

Unusual volume stocks are being observed in Wednesday's session. ↗

October 01, 2025

Via Chartmill

Here are the top movers in Tuesday's session. ↗

September 30, 2025

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

September 30, 2025

Via Benzinga

These stocks are moving in today's session ↗

September 30, 2025

Via Chartmill

Frequently Asked Questions

Is Zura Bio Limited - Class A Ordinary shares publicly traded?

Yes, Zura Bio Limited - Class A Ordinary shares is publicly traded.

What exchange does Zura Bio Limited - Class A Ordinary shares trade on?

Zura Bio Limited - Class A Ordinary shares trades on the Nasdaq Stock Market

What is the ticker symbol for Zura Bio Limited - Class A Ordinary shares?

The ticker symbol for Zura Bio Limited - Class A Ordinary shares is ZURA on the Nasdaq Stock Market

What is the current price of Zura Bio Limited - Class A Ordinary shares?

The current price of Zura Bio Limited - Class A Ordinary shares is 5.405

When was Zura Bio Limited - Class A Ordinary shares last traded?

The last trade of Zura Bio Limited - Class A Ordinary shares was at 08/03/26 11:34 AM ET

What is the market capitalization of Zura Bio Limited - Class A Ordinary shares?

The market capitalization of Zura Bio Limited - Class A Ordinary shares is 335.46M

How many shares of Zura Bio Limited - Class A Ordinary shares are outstanding?

Zura Bio Limited - Class A Ordinary shares has 335M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.